TriSalus Life Sciences announced its financial results for the third quarter ended September 30, 2024, reporting revenue of $7.3 million from the sale of the TriNav system, a 42% increase compared to the same period in 2023. Year-to-date revenue reached $21.2 million, marking a 66% increase over the first nine months of 2023.
The company achieved gross margins of 86% for the third quarter of 2024, with operating losses narrowing to $8.7 million, a significant improvement from $18.6 million in Q3 2023. Net losses available to common stockholders were $2.4 million for the quarter, compared to $1.4 million in the prior year period.
As of September 30, 2024, cash and cash equivalents totaled $11.3 million. TriSalus provided 2025 guidance, projecting greater than 50% revenue growth, a greater than 20% reduction in operating expenses, positive full-year EBITDA, and positive cash flow in the second half of 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.